DeepMed Research

DANA-FARBER CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1947-01-01

Employees: -

Market Cap: -

Website: http://www.dana-farber.org/

Clinical Trials

Effects of Bortezomib-Based Therapy on Cellular Immunity and Response to DC/Myeloma Fusion Vaccines in Vitro

Completed

Conditions: Multiple Myeloma

Interventions: Procedure: Blood draws

First Posted Date: 2011-11-16

Last Posted Date: 2018-01-11

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 11

Registration Number: NCT01472627

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Carfilzomib, Rituximab and Dexamethasone in Waldenstrom's Macroglobulinemia

Phase 2

Completed

Conditions: Waldenstrom's Macroglobulinemia

Interventions: Drug: Dexamethasone
Drug: Carfilzomib
Drug: Rituximab

First Posted Date: 2011-11-11

Last Posted Date: 2018-11-20

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 31

Registration Number: NCT01470196

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

The Young Women's Breast Cancer Study

Active, not recruiting

Conditions: Breast Cancer

First Posted Date: 2011-11-09

Last Posted Date: 2025-04-22

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 1302

Registration Number: NCT01468246

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
DF/BWCC at Milford Regional Medical Center, Milford, Massachusetts, United States
🇺🇸
Newton-Wellesley Hospital, Newton, Massachusetts, United States

and more 10 locations

Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

Phase 2

Completed

Conditions: Pancreatic Neuroendocrine Tumor
Carcinoid Tumor

Interventions: Drug: Cabozantinib

First Posted Date: 2011-11-06

Last Posted Date: 2024-03-05

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 61

Registration Number: NCT01466036

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Ofatumumab With High Dose Methylprednisone Followed by Ofatumumab and Alemtuzumab in 17p CLL

Phase 2

Terminated

Conditions: CLL
SLL

Interventions: Drug: Ofatumumab
Drug: High-Dose Methylprednisolone
Drug: Alemtuzumab

First Posted Date: 2011-11-04

Last Posted Date: 2023-08-29

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 30

Registration Number: NCT01465334

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Multiple Risk Behavior Intervention in Health Care Settings

Not Applicable

Completed

Conditions: Health Behavior
Risk Reduction Behavior

Interventions: Behavioral: HD2+
Behavioral: HD2

First Posted Date: 2011-08-12

Last Posted Date: 2018-12-19

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 2440

Registration Number: NCT01415492

Locations: 🇺🇸
Harvard Vanguard Medical Associates, Boston, Massachusetts, United States

SNP-Based Prediction of Oral Mucositis Risk in Patients Receiving Hematopoietic Stem Cell Transplants (HSCT)

Completed

Conditions: Non-Hodgkin's Lymphoma
Hodgkin's Lymphoma
Multiple Myeloma

First Posted Date: 2011-07-26

Last Posted Date: 2013-07-16

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 181

Registration Number: NCT01402687

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Image-Guided Gynecologic Brachytherapy

Phase 2

Completed

Conditions: Carcinoma of the Vulva
Cervical Cancer
Vaginal Cancer
Uterine Cancer

Interventions: Procedure: Image-guided brachytherapy
Drug: 3'-Deoxy-3'-18f-Fluorothymidine

First Posted Date: 2011-07-22

Last Posted Date: 2023-03-14

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 93

Registration Number: NCT01399658

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

Enhancing Adherence and Knowledge of Erlotinib in Patients Wtih Non-Small Cell Lung Cancer

Not Applicable

Completed

Conditions: Lung Cancer

First Posted Date: 2011-06-22

Last Posted Date: 2012-06-26

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 30

Registration Number: NCT01378598

Daily IL-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease

Phase 2

Active, not recruiting

Conditions: Chronic Graft-versus-host Disease

Interventions: Drug: Interleukin-2

First Posted Date: 2011-06-03

Last Posted Date: 2025-02-25

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 35

Registration Number: NCT01366092

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy